U.S. License Holder:
Apotex / Ambio
Date of License:
November-16-2023
Last Update:
Dec-15-2024
FDA-Approved Indications
TERIPARATIDE APOTEX (teriparatide) is a parathyroid hormone analog (PTH 1-34) indicated for:
Treatment of postmenopausal women with osteoporosis at high risk for fracture;
Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture;
Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture.